Abstract
Chimeric antigen receptor-engineered T-cell (CAR-T) therapy is a type of adoptive cellular immunotherapy, in which T cells isolated from patients’ or donors’ peripheral blood mononuclear cells are genetically modified, expanded, and reinfused to patients. CAR-T therapy has resulted in encouraging outcomes in patients with B-cell malignancies and is currently being investigated for the treatment of other hematological malignancies. This review discusses the basic structure of CAR, the evolution of CAR structure, the advances in acute leukemia therapy, and the innovative strategies in CAR design and CAR-T production.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
